Connection

Michael Lilly to Humans

This is a "connection" page, showing publications Michael Lilly has written about Humans.
Connection Strength

0.418
  1. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. Prostate. 2022 09; 82(13):1264-1272.
    View in: PubMed
    Score: 0.032
  2. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019 05 01; 125(9):1459-1469.
    View in: PubMed
    Score: 0.025
  3. Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy. Protein Eng Des Sel. 2017 12 01; 30(12):785-793.
    View in: PubMed
    Score: 0.023
  4. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
    View in: PubMed
    Score: 0.017
  5. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
    View in: PubMed
    Score: 0.015
  6. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
    View in: PubMed
    Score: 0.014
  7. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008 Jul 25; 283(30):20635-44.
    View in: PubMed
    Score: 0.012
  8. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007 Jan; 6(1):163-72.
    View in: PubMed
    Score: 0.011
  9. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67.
    View in: PubMed
    Score: 0.009
  10. Crosstalk between pro-survival sphingolipid metabolism and complement signaling induces inflammasome-mediated tumor metastasis. Cell Rep. 2022 12 06; 41(10):111742.
    View in: PubMed
    Score: 0.008
  11. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist. 2022 Oct 01; 27(10):e815-e818.
    View in: PubMed
    Score: 0.008
  12. Differential Circulating Fungal Microbiome in Prostate Cancer Patients Compared to Healthy Control Individuals. J Immunol Res. 2022; 2022:2574964.
    View in: PubMed
    Score: 0.008
  13. Diphtheria toxin conjugate therapy of cancer. Cancer Chemother Biol Response Modif. 2002; 20:301-13.
    View in: PubMed
    Score: 0.008
  14. A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021 Nov; 143:112226.
    View in: PubMed
    Score: 0.008
  15. Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. Oncoimmunology. 2021; 10(1):1959101.
    View in: PubMed
    Score: 0.007
  16. Racial Differences in Patient Portal Activation and Research Enrollment Among Patients With Prostate Cancer. JCO Clin Cancer Inform. 2021 06; 5:768-774.
    View in: PubMed
    Score: 0.007
  17. Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation. Blood. 2001 Mar 15; 97(6):1662-70.
    View in: PubMed
    Score: 0.007
  18. Financial toxicity and strain among men receiving prostate cancer care in an equal access healthcare system. Cancer Med. 2020 12; 9(23):8765-8771.
    View in: PubMed
    Score: 0.007
  19. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193.
    View in: PubMed
    Score: 0.007
  20. Social and clinical determinants of physical activity in prostate cancer survivors. Support Care Cancer. 2021 Jan; 29(1):459-465.
    View in: PubMed
    Score: 0.007
  21. Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients. Ethn Dis. 2020; 30(Suppl 1):185-192.
    View in: PubMed
    Score: 0.007
  22. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 06 01; 26(11):2546-2555.
    View in: PubMed
    Score: 0.007
  23. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-?. Sci Transl Med. 2020 01 08; 12(525).
    View in: PubMed
    Score: 0.007
  24. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. Oncologist. 2020 04; 25(4):327-333.
    View in: PubMed
    Score: 0.007
  25. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat. 2019 Feb; 173(3):559-571.
    View in: PubMed
    Score: 0.006
  26. The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer. Front Immunol. 2018; 9:1188.
    View in: PubMed
    Score: 0.006
  27. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res. 1997 Dec 01; 57(23):5348-55.
    View in: PubMed
    Score: 0.006
  28. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma. Oncotarget. 2016 Dec 13; 7(50):83514-83529.
    View in: PubMed
    Score: 0.005
  29. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget. 2015 Dec 08; 6(39):41809-24.
    View in: PubMed
    Score: 0.005
  30. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther. 2015 Dec; 14(12):2744-52.
    View in: PubMed
    Score: 0.005
  31. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8.
    View in: PubMed
    Score: 0.005
  32. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis. 2014 Oct; 35(10):2321-30.
    View in: PubMed
    Score: 0.005
  33. Generation of "virtual" control groups for single arm prostate cancer adjuvant trials. PLoS One. 2014; 9(1):e85010.
    View in: PubMed
    Score: 0.004
  34. Recovery of renal function among ESRD patients in the US medicare program. PLoS One. 2013; 8(12):e83447.
    View in: PubMed
    Score: 0.004
  35. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7(10):e46737.
    View in: PubMed
    Score: 0.004
  36. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013 Mar; 27(3):586-94.
    View in: PubMed
    Score: 0.004
  37. Stakeholder perspectives on transitions of nursing home residents to hospital emergency departments and back in two Canadian provinces. J Aging Stud. 2012 Dec; 26(4):419-27.
    View in: PubMed
    Score: 0.004
  38. Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene. 1992 Apr; 7(4):727-32.
    View in: PubMed
    Score: 0.004
  39. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One. 2012; 7(2):e31213.
    View in: PubMed
    Score: 0.004
  40. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia. 1991 Apr; 5(4):283-7.
    View in: PubMed
    Score: 0.004
  41. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia. 2011 Feb; 13(2):108-19.
    View in: PubMed
    Score: 0.004
  42. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate. 2011 May 15; 71(7):755-65.
    View in: PubMed
    Score: 0.004
  43. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res. 1990 Sep 01; 50(17):5520-5.
    View in: PubMed
    Score: 0.004
  44. Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem. 2010 Sep 17; 285(38):29128-37.
    View in: PubMed
    Score: 0.003
  45. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res. 2010 Aug; 8(8):1126-41.
    View in: PubMed
    Score: 0.003
  46. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010 Feb; 16(2):205-13.
    View in: PubMed
    Score: 0.003
  47. PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications. Int J Exp Pathol. 2010 Feb; 91(1):34-43.
    View in: PubMed
    Score: 0.003
  48. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer. 2009 Aug 28; 8:68.
    View in: PubMed
    Score: 0.003
  49. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009 Jun; 8(6):1473-83.
    View in: PubMed
    Score: 0.003
  50. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther. 2009 May; 8(9):846-53.
    View in: PubMed
    Score: 0.003
  51. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 1989 Mar 01; 49(5):1287-93.
    View in: PubMed
    Score: 0.003
  52. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. 2008 Sep; 118(9):3038-50.
    View in: PubMed
    Score: 0.003
  53. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer. 2008 Oct; 44(15):2144-51.
    View in: PubMed
    Score: 0.003
  54. Leukemia-differentiating activity expressed by the human melanoma cell line LD-1. Leuk Res. 1988; 12(3):217-25.
    View in: PubMed
    Score: 0.003
  55. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia. 2008 Jan; 22(1):138-46.
    View in: PubMed
    Score: 0.003
  56. Production of granulocyte colony-stimulating factor by a human melanoma cell line. Exp Hematol. 1987 Oct; 15(9):966-71.
    View in: PubMed
    Score: 0.003
  57. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem. 2007 Oct 01; 15(19):6463-73.
    View in: PubMed
    Score: 0.003
  58. Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res. 2007 Feb 15; 67(4):1769-74.
    View in: PubMed
    Score: 0.003
  59. Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene. 2007 Aug 02; 26(35):5145-53.
    View in: PubMed
    Score: 0.003
  60. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51.
    View in: PubMed
    Score: 0.002
  61. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 2005 Feb 15; 105(4):1759-67.
    View in: PubMed
    Score: 0.002
  62. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003 Jan-Feb; 23(1A):167-78.
    View in: PubMed
    Score: 0.002
  63. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood. 1998 Dec 01; 92(11):4279-86.
    View in: PubMed
    Score: 0.002
  64. Cytoplasmic domains of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor beta chain (hbetac) responsible for human GM-CSF-induced myeloid cell differentiation. J Biol Chem. 1998 Jul 31; 273(31):19411-8.
    View in: PubMed
    Score: 0.002
  65. Concept formation and problem-solving following closed head injury in children. J Int Neuropsychol Soc. 1997 Nov; 3(6):598-607.
    View in: PubMed
    Score: 0.001
  66. The cytoplasmic domain of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor alpha subunit is essential for both GM-CSF-mediated growth and differentiation. J Biol Chem. 1997 Jul 11; 272(28):17450-9.
    View in: PubMed
    Score: 0.001
  67. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 1995 Sep 01; 55(17):3716-20.
    View in: PubMed
    Score: 0.001
  68. Mapping the intracytoplasmic regions of the alpha granulocyte-macrophage colony-stimulating factor receptor necessary for cell growth regulation. J Biol Chem. 1994 May 20; 269(20):14607-13.
    View in: PubMed
    Score: 0.001
  69. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood. 1993 Jan 15; 81(2):357-64.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.